[go: up one dir, main page]

MX2018000505A - Anticuerpos especificos para tau hiperfosforilada y metodos de uso de los mismos. - Google Patents

Anticuerpos especificos para tau hiperfosforilada y metodos de uso de los mismos.

Info

Publication number
MX2018000505A
MX2018000505A MX2018000505A MX2018000505A MX2018000505A MX 2018000505 A MX2018000505 A MX 2018000505A MX 2018000505 A MX2018000505 A MX 2018000505A MX 2018000505 A MX2018000505 A MX 2018000505A MX 2018000505 A MX2018000505 A MX 2018000505A
Authority
MX
Mexico
Prior art keywords
tau
methods
hyperfosphoriled
same
specific antibodies
Prior art date
Application number
MX2018000505A
Other languages
English (en)
Other versions
MX392396B (es
Inventor
Torleif Pedersen Jan
Østergaard Pedersen Lars
Claus Alfred Dächsel Justus
Abdur-Rasheed Asuni Ayodeji
Rosenqvist Nina
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1512211.2A external-priority patent/GB201512211D0/en
Priority claimed from GBGB1518375.9A external-priority patent/GB201518375D0/en
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of MX2018000505A publication Critical patent/MX2018000505A/es
Publication of MX392396B publication Critical patent/MX392396B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)

Abstract

La presente invención se relaciona con una nueva clase de anticuerpo monoclonal que se une de forma específica al resto fosforilado de serina 396 en la tau patológica hiperfosforilada (PHF) (pS396), así como a métodos de uso de estas moléculas y sus fragmentos de unión tau en el tratamiento de la enfermedad de Alzheimer y de las taupatías.
MX2018000505A 2015-07-13 2016-07-12 Anticuerpos especificos para tau hiperfosforilada y metodos de uso de los mismos. MX392396B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1512211.2A GB201512211D0 (en) 2015-07-13 2015-07-13 Agents, uses and methods
GBGB1518375.9A GB201518375D0 (en) 2015-10-16 2015-10-16 Agents,uses and methods
PCT/EP2016/066470 WO2017009308A2 (en) 2015-07-13 2016-07-12 Antibodies specific for hyperphosphorylated tau and methods of use thereof

Publications (2)

Publication Number Publication Date
MX2018000505A true MX2018000505A (es) 2018-04-30
MX392396B MX392396B (es) 2025-03-24

Family

ID=56557664

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018000505A MX392396B (es) 2015-07-13 2016-07-12 Anticuerpos especificos para tau hiperfosforilada y metodos de uso de los mismos.

Country Status (30)

Country Link
US (4) US10196439B2 (es)
EP (1) EP3322442A2 (es)
JP (1) JP6878395B2 (es)
KR (1) KR20180030047A (es)
CN (1) CN107847595B (es)
AU (1) AU2016292892B2 (es)
BR (1) BR112018000769A2 (es)
CL (1) CL2018000096A1 (es)
CO (1) CO2017013318A2 (es)
CR (1) CR20180026A (es)
DO (1) DOP2018000012A (es)
EA (1) EA038703B1 (es)
EC (1) ECSP18002644A (es)
GE (2) GEP20227369B (es)
HK (1) HK1254357A1 (es)
IL (1) IL256791B (es)
JO (1) JO3711B1 (es)
MA (1) MA42446A (es)
MX (1) MX392396B (es)
NI (1) NI201800005A (es)
PE (1) PE20180607A1 (es)
PH (1) PH12018500062A1 (es)
RU (1) RU2727911C2 (es)
SG (1) SG10202101343RA (es)
SV (1) SV2018005611A (es)
TN (1) TN2017000541A1 (es)
TW (1) TWI741987B (es)
UA (1) UA123862C2 (es)
WO (1) WO2017009308A2 (es)
ZA (1) ZA201800070B (es)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10501531B2 (en) 2013-03-13 2019-12-10 Prothena Biosciences Limited Tau immunotherapy
JO3627B1 (ar) 2015-04-30 2020-08-27 H Lundbeck As إيميدازو بيرازينونات على هيئة مثبطات pde1
CA2986942C (en) 2015-06-05 2025-07-22 Ac Immune Sa Anti-tau antibodies and their methods of use
KR102742965B1 (ko) 2015-07-06 2024-12-13 유씨비 바이오파마 에스알엘 타우 결합 항체
JO3711B1 (ar) 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
CN109415432B (zh) 2016-05-02 2022-07-08 普罗塞纳生物科学有限公司 Tau免疫疗法
EA201892417A1 (ru) 2016-05-02 2019-05-31 Протена Биосайенсис Лимитед Антитела, распознающие тау
US10034861B2 (en) 2016-07-04 2018-07-31 H. Lundbeck A/S 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors
HRP20210522T1 (hr) 2016-07-12 2021-05-14 H. Lundbeck A/S Antitijela specifična za hiperfosforilirani tau i načini njihove uporabe
WO2018035137A1 (en) * 2016-08-15 2018-02-22 The Board Of Regents Of The University Of Texas System Volume control device for manually operated resuscitator and ventilation apparatus and method of use
AU2017350473A1 (en) 2016-10-28 2019-04-18 H. Lundbeck A/S Combination treatments comprising imidazopyrazinones for the treatment of psychiatric and/or cognitive disorders
AU2017350477A1 (en) 2016-10-28 2019-04-18 H. Lundbeck A/S Combination treatments comprising administration of imidazopyrazinones
AU2017373884B2 (en) 2016-12-07 2024-11-14 Ac Immune Sa Anti-tau antibodies and methods of their use
AU2017373889B2 (en) 2016-12-07 2025-01-02 Ac Immune Sa Anti-Tau antibodies and methods of use
WO2018127519A1 (en) * 2017-01-04 2018-07-12 H. Lundbeck A/S Antibodies specific for hyperphosphorylated tau for the treatment of ocular diseases
MX2019009817A (es) 2017-02-17 2019-11-21 Denali Therapeutics Inc Anticuerpos anti-tau y metodos de uso de los mismos.
JOP20180014A1 (ar) 2017-02-27 2019-01-30 Teijin Pharma Ltd جسم مضاد متوافق مع البشر لعلاج أو الوقاية من الاضطرابات الإدراكية، وعملية لإنتاجه، وعامل لعلاج أو الوقاية من الاضطرابات الإدراكية باستخدامه
EA039569B1 (ru) * 2017-03-14 2022-02-11 Х. Лундбекк А/С Антитела, специфичные к гиперфосфорилированному тау-белку, и способы их применения
MY206891A (en) 2017-05-02 2025-01-13 Prothena Biosciences Ltd Antibodies recognizing tau
WO2019023247A1 (en) 2017-07-25 2019-01-31 Immutics, Inc. TREATMENT OF CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND ITS LIGAND
CA3077247A1 (en) 2017-10-16 2019-04-25 Eisai R & D Management Co., Ltd. Anti-tau antibodies and uses thereof
AR113926A1 (es) 2017-12-14 2020-07-01 H Lundbeck As Derivados de 1h-pirazolo[4,3-b]piridinas
PT3723807T (pt) 2017-12-14 2021-11-26 H Lundbeck As Tratamentos de associação que compreendem a administração de 1h-pirazolo[4,3-b]piridinas
CN117447475A (zh) 2017-12-20 2024-01-26 H.隆德贝克有限公司 作为PDE1抑制剂的吡唑并[4,3-b]吡啶和咪唑并[1,5-a]嘧啶
CA3089923A1 (en) * 2018-02-01 2019-08-08 Janssen Vaccines & Prevention B.V. Binding molecules that specifically bind to tau
CN116063505B (zh) 2019-01-30 2024-05-03 真和制药有限公司 抗gal3抗体及其用途
TWI859197B (zh) 2019-03-03 2024-10-21 愛爾蘭商普羅帝納生物科學公司 識別ｔａｕ之抗體
JP7566766B2 (ja) 2019-03-11 2024-10-15 ヤンセン バイオテツク，インコーポレーテツド 抗Ｖβ１７／抗ＣＤ１２３二重特異性抗体
CN113748343A (zh) 2019-03-28 2021-12-03 H.隆德贝克有限公司 pS396测定用于诊断TAU蛋白病的用途
GB201909393D0 (en) * 2019-06-28 2019-08-14 Gen2 Neuroscience Ltd Tau epitope and binding molecules
SG10201908922UA (en) * 2019-09-25 2021-04-29 Sengenics Corp Pte Ltd Identification of health status in the elderly using immunological biomarkers
IL297200A (en) 2020-04-15 2022-12-01 Voyager Therapeutics Inc tau binding compounds
EP4157338A4 (en) 2020-05-26 2024-11-13 TrueBinding, Inc. METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING
IL299292A (en) 2020-06-25 2023-02-01 Merck Sharp & Dohme Llc High-affinity antibodies to tau phosphorylated at serine 413
UY39373A (es) 2020-08-10 2022-02-25 Janssen Biotech Inc Materiales y métodos para producir linfocitos específicos de virus diseñados mediante bioingeniería
WO2022056199A1 (en) * 2020-09-11 2022-03-17 Janssen Biotech, Inc. Multi-specific immune targeting molecules and uses thereof
WO2022056192A1 (en) 2020-09-11 2022-03-17 Janssen Biotech, Inc. Methods and compositions for modulating beta chain mediated immunity
US12448449B2 (en) 2020-09-11 2025-10-21 Janssen Biotech, Inc. Immune targeting molecules and uses thereof
WO2022104136A2 (en) * 2020-11-12 2022-05-19 Children's Medical Center Corporation Methods and compositions for tauopathy diagnosis and treatment
JP2023554382A (ja) 2020-12-16 2023-12-27 ボイジャー セラピューティクス インコーポレイテッド タウ結合化合物
CL2021001380A1 (es) 2021-05-26 2022-01-14 Corporacion Centro Int De Biomedicina Icc Generación de un nuevo anticuerpo monoclonal sitio específico para la proteína tau y su uso como herramienta en biomarcadores específicos para la detección temprana de enfermedades neurodegenerativas y patologías involucradas con la proteína tau como alzheimer y otras demencias.
CN113702647B (zh) * 2021-08-31 2024-03-15 普十生物科技(北京)有限公司 人生长分化因子15即时检测试剂盒、其制备方法及其应用
US20250034559A1 (en) 2021-11-17 2025-01-30 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
EP4543473A1 (en) 2022-06-22 2025-04-30 Voyager Therapeutics, Inc. Tau binding compounds
WO2024059739A1 (en) 2022-09-15 2024-03-21 Voyager Therapeutics, Inc. Tau binding compounds
EP4595977A1 (en) * 2022-09-26 2025-08-06 Waterstone Pharmaceuticals (Wuhan) Co., Ltd. Ultra-long-acting platform comprising fc-advanced fatty acid chain
CN116794328A (zh) * 2023-06-20 2023-09-22 南京鼓楼医院 一种基于多位点的高灵敏磷酸化Tau蛋白检测方法
CN116754776A (zh) * 2023-06-20 2023-09-15 南京鼓楼医院 一种基于S396与S404位点的高灵敏磷酸化Tau蛋白检测方法
WO2025122634A1 (en) 2023-12-05 2025-06-12 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
DE3380726D1 (en) 1982-06-24 1989-11-23 Japan Chem Res Long-acting composition
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4735210A (en) 1985-07-05 1988-04-05 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5101827A (en) 1985-07-05 1992-04-07 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4861581A (en) 1986-12-05 1989-08-29 Cancer Biologics, Inc. Detection of necrotic malignant tissue and associated therapy
US5750172A (en) 1987-06-23 1998-05-12 Pharming B.V. Transgenic non human mammal milk
US5648471A (en) 1987-12-03 1997-07-15 Centocor, Inc. One vial method for labeling antibodies with Technetium-99m
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
AU650629B2 (en) 1989-08-09 1994-06-30 Rhomed Incorporated Direct radiolabeling of antibodies and other proteins with technetium or rhenium
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
DK0814159T3 (da) 1990-08-29 2005-10-24 Genpharm Int Transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
AU2235992A (en) 1991-06-14 1993-01-12 Genpharm International, Inc. Transgenic immunodeficient non-human animals
WO1993001227A1 (en) 1991-07-08 1993-01-21 University Of Massachusetts At Amherst Thermotropic liquid crystal segmented block copolymer
AU681071B2 (en) 1991-12-06 1997-08-21 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Tools for the diagnosis and treatment of alzheimer's disease
EP0746609A4 (en) 1991-12-17 1997-12-17 Genpharm Int NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES
ES2146648T3 (es) 1993-03-09 2000-08-16 Genzyme Corp Procedimiento de aislamiento de proteinas de la leche.
CA2161351C (en) 1993-04-26 2010-12-21 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US6077835A (en) 1994-03-23 2000-06-20 Case Western Reserve University Delivery of compacted nucleic acid to cells
KR970029803A (ko) 1995-11-03 1997-06-26 김광호 반도체 메모리장치의 프리차지 회로
DK1150918T3 (da) 1999-02-03 2004-12-20 Biosante Pharmaceuticals Inc Fremgangsmåde til fremstilling af terapeutiske calciumphosphatpartikler
US6281005B1 (en) 1999-05-14 2001-08-28 Copernicus Therapeutics, Inc. Automated nucleic acid compaction device
EP1210372B1 (en) 1999-07-29 2008-01-23 Medarex, Inc. Human monoclonal antibodies to her2/neu
KR20020047132A (ko) 1999-08-24 2002-06-21 메다렉스, 인코포레이티드 인간 씨티엘에이-4 항체 및 그의 용도
US20030162230A1 (en) * 2000-09-27 2003-08-28 Reagan Kevin J. Method for quantifying phosphokinase activity on proteins
ES2295228T3 (es) 2000-11-30 2008-04-16 Medarex, Inc. Roedores transcromosomicos transgenicos para la preparacion de anticuerpos humanos.
US6881557B2 (en) 2001-07-12 2005-04-19 Arrowsmith Technologies Llp Super humanized antibodies
US8003108B2 (en) * 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
EP1940442A4 (en) 2005-08-04 2009-08-19 Einstein Coll Med Phosphorylation of tau by abl
EA016609B1 (ru) 2005-11-28 2012-06-29 Генмаб А/С Рекомбинантные моновалентные антитела и способы их получения
WO2009097006A2 (en) 2007-08-10 2009-08-06 Medarex, Inc. Hco32 and hco27 and related examples
EP2527369A3 (en) 2007-09-13 2012-12-19 University Of Zurich Prorektorat Forschung Monoclonal amyloid beta (abeta)-specific antibody and uses thereof
EP4218794A3 (en) 2009-06-10 2023-09-13 New York University Immunological targeting of pathological tau proteins
US8609097B2 (en) * 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
IN2012DN03343A (es) 2009-10-26 2015-10-23 Otsuka Pharma Co Ltd
SI2625198T1 (sl) * 2010-10-07 2015-11-30 Ac Immune S.A. Epfl Innovation Park Protitelesa, ki prepoznavajo fosfo-tau
NZ609984A (en) 2010-10-11 2015-05-29 Biogen Idec Internat Neuroscience Gmbh Human anti-tau antibodies
PL2758433T3 (pl) * 2011-09-19 2018-06-29 Axon Neuroscience Se Oparta na białku terapia i diagnozowanie patologii zależnej od Tau w chorobie Alzheimera
AR092779A1 (es) * 2011-10-07 2015-05-06 Ac Immune Sa Composicon farmaceutica que comprende anticuerpos que se unen a conformeros de proteinas tau
BR112014024769A2 (pt) 2012-04-05 2017-12-12 Ac Immune Sa anticorpo humanizado tau
EP3838921A3 (en) 2012-07-03 2021-09-01 Washington University Antibodies to tau
JP6290212B2 (ja) 2012-08-16 2018-03-07 アイピエリアン，インコーポレイティド タウオパチーの処置方法
US10501531B2 (en) 2013-03-13 2019-12-10 Prothena Biosciences Limited Tau immunotherapy
EP2986713A1 (en) * 2013-04-16 2016-02-24 Glykos Finland Oy A method for generating induced pluripotent stem cells
WO2016007414A1 (en) 2014-07-08 2016-01-14 New York University Tau imaging ligands and their uses in the diagnosis and treatment of tauopathy
JO3711B1 (ar) 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
HRP20210522T1 (hr) 2016-07-12 2021-05-14 H. Lundbeck A/S Antitijela specifična za hiperfosforilirani tau i načini njihove uporabe
US10364286B2 (en) * 2016-12-22 2019-07-30 H. Lundbeck A/S Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation
WO2018127519A1 (en) 2017-01-04 2018-07-12 H. Lundbeck A/S Antibodies specific for hyperphosphorylated tau for the treatment of ocular diseases
US10934438B2 (en) 2017-04-27 2021-03-02 Axalta Coating Systems Ip Co., Llc Coatings and methods for using and producing the same

Also Published As

Publication number Publication date
ECSP18002644A (es) 2018-03-31
TWI741987B (zh) 2021-10-11
GEAP202114672A (en) 2021-11-10
NI201800005A (es) 2018-10-19
AU2016292892B2 (en) 2021-11-18
RU2018100822A3 (es) 2019-12-26
US20200190178A1 (en) 2020-06-18
JP2018531580A (ja) 2018-11-01
DOP2018000012A (es) 2018-02-28
TN2017000541A1 (en) 2019-04-12
CN107847595A (zh) 2018-03-27
MA42446A (fr) 2018-05-23
WO2017009308A2 (en) 2017-01-19
US20190177401A1 (en) 2019-06-13
CO2017013318A2 (es) 2018-05-21
PE20180607A1 (es) 2018-04-09
US10196439B2 (en) 2019-02-05
CL2018000096A1 (es) 2018-07-06
JO3711B1 (ar) 2021-01-31
WO2017009308A3 (en) 2017-04-06
IL256791A (en) 2018-03-29
ZA201800070B (en) 2019-04-24
JP6878395B2 (ja) 2021-05-26
US11739140B2 (en) 2023-08-29
EA201890039A1 (ru) 2018-08-31
AU2016292892A1 (en) 2018-01-18
EA038703B1 (ru) 2021-10-07
MX392396B (es) 2025-03-24
RU2727911C2 (ru) 2020-07-24
BR112018000769A2 (pt) 2018-09-25
RU2018100822A (ru) 2019-08-13
US20210206843A1 (en) 2021-07-08
SV2018005611A (es) 2018-02-23
GEP20227369B (en) 2022-04-11
IL256791B (en) 2022-09-01
US10934348B2 (en) 2021-03-02
EP3322442A2 (en) 2018-05-23
US10562962B2 (en) 2020-02-18
SG10202101343RA (en) 2021-03-30
HK1254357A1 (zh) 2019-07-19
CA2990555A1 (en) 2017-01-19
CN107847595B (zh) 2021-09-24
NZ738595A (en) 2022-07-01
UA123862C2 (uk) 2021-06-16
US20170015738A1 (en) 2017-01-19
TW201716436A (zh) 2017-05-16
PH12018500062A1 (en) 2018-07-09
KR20180030047A (ko) 2018-03-21
CR20180026A (es) 2018-03-08

Similar Documents

Publication Publication Date Title
MX2018000505A (es) Anticuerpos especificos para tau hiperfosforilada y metodos de uso de los mismos.
MX2019000476A (es) Anticuerpos especificos para la tau hiperfosforilada y sus metodos de uso.
CO2017012974A2 (es) Anticuerpos de unión a tau
EA201892362A1 (ru) Агонистические антитела, которые связываются с cd40 человека, и варианты их применения
CO2017012971A2 (es) Anticuerpos de unión a tau
MX2022014914A (es) Compuestos de interaccion con glicanos y metodos de uso.
CU20170169A7 (es) Anticuerpos de factor xi
CU20180024A7 (es) Moléculas de unión a linfopoyetina estromal tímica (tslp), composiciones farmacéuticas que las contienen y método de producción de las mismas
EA201892440A1 (ru) Антитела к tl1a и их применения
UA123202C2 (uk) Антитіло до тау-білка і його застосування
EA202191666A1 (ru) Антитела к il-27 и их применение
CR20190012A (es) Anticuerpos específicos para la tauy hiperfosforilada y sus métodos de uso
AR109258A1 (es) Anticuerpos específicos para la tau hiperfosforilada y sus métodos de uso
AR105333A1 (es) Anticuerpos específicos para tau hiperfosforilada y métodos de uso de los mismos
EA201892570A1 (ru) Антитела, специфичные к гиперфосфорилированному тау-белку, и способы их применения